Jabbar Ahmad, Arruda Suleima, Sadick Neil
J Drugs Dermatol. 2017 May 1;16(5):489-494.
Injectable soft-tissue augmentation agents have become popular alternatives to surgical procedures for the aging face and body. In contrast to temporary, space-occupying replacement fillers such as collagen-based and hyaluronic acid products, poly-l-lactic acid (PLLA) has been demonstrated to gradually promotes deposition of collagen via a biostimulatory response, with therapeutic effects lasting approximately two years. In 2004, the FDA approved its use for rejuvenation of facial contours secondary to lipoatrophy associated with antiretroviral therapy for HIV infection. By 2009 PLLA was FDA-approved for the correction of nasolabial fold contour deficiencies and other lines and wrinkles. There have since been limited but promising results with off-label use of PLLA for nonfacial volumization as well, including the hands, neck/décolleté, abdomen, and gluteal area. The objective of this article is to review clinical evidence, current trends, and technical considerations for the use of PLLA for nonfacial, body rejuvenation.
J Drugs Dermatol. 2017;16(5):489-494.
.可注射软组织填充剂已成为面部和身体抗衰手术的热门替代方案。与基于胶原蛋白和透明质酸产品等临时性、占位性替代填充剂不同，聚左旋乳酸（PLLA）已被证明可通过生物刺激反应逐渐促进胶原蛋白沉积，治疗效果持续约两年。2004年，美国食品药品监督管理局（FDA）批准其用于改善因抗逆转录病毒疗法治疗HIV感染所致脂肪萎缩引起的面部轮廓。到2009年，PLLA被FDA批准用于矫正鼻唇沟轮廓缺陷及其他皱纹。此后，PLLA用于非面部组织容量增加（包括手部、颈部/锁骨上区、腹部和臀部）的非适应证使用也取得了有限但令人鼓舞的结果。本文的目的是综述PLLA用于非面部身体抗衰的临床证据、当前趋势和技术考量。
《皮肤药物学杂志》。2017年；16(5):489 - 494。
